AVATAMED is a global precision medicine company based in Singapore. It is spin-off from the international PuRPOSE Research Programme between Samsung Medical Centre, A*STAR Singapore, National Cancer Centre Singapore and National University of Singapore. AVATAMED apply the AVATASCAN high-throughput (HTS) and high-content (HCS) drug screening technology to screen patient-derived tumour cells across a panel of drugs to determine drug sensitivities and resistances.

The AVATASCAN platform, together with genomic and immune profiling, offers Pharmaceutical Companies to screen their drug candidates in clinical trials and drug development, and oncologists to suggest the most optimal drug treatment personalised to their patients.